Wednesday, January 27, 2016 1:56:11 PM
What bullshit. I prefer reality:
(1) It's reckless to assume that every single man, woman, and child will buy the drug at full value rather than something based in reality that a relatively much smaller percentage of the people.
(2) It's reckless to refer to $45 million in mythical sales as net income -- $0 allocated for cost of the drugs or overhead which are already significant.
(3) P/E ratios are a statistic based on EARNINGS -- you applied a mythical pie-in-the-sky sales figure in place of earnings.
(4) If we ran with the laughable ASSumption that everybody with a disease got cured by NNVC, there would be little if anybody left the following year to cure! The 45,000 people per year who get the disease need to get it from UNCURED people for the most part otherwise the numbers diminish to zero.
Better ASSumption, yet still wildly optimistic, would be say 25% take the drug so there are still plenty of new and uncured people to keep it spreading. Your $45 million goes down to $12.5 million and barely any profit if any at all. It would realistically bring the company a lot closer to break-even at best which is great but still no earnings level to even justify the current share price $12 to $100 ridiculous targets.
(1) It's reckless to assume that every single man, woman, and child will buy the drug at full value rather than something based in reality that a relatively much smaller percentage of the people.
(2) It's reckless to refer to $45 million in mythical sales as net income -- $0 allocated for cost of the drugs or overhead which are already significant.
(3) P/E ratios are a statistic based on EARNINGS -- you applied a mythical pie-in-the-sky sales figure in place of earnings.
(4) If we ran with the laughable ASSumption that everybody with a disease got cured by NNVC, there would be little if anybody left the following year to cure! The 45,000 people per year who get the disease need to get it from UNCURED people for the most part otherwise the numbers diminish to zero.
Better ASSumption, yet still wildly optimistic, would be say 25% take the drug so there are still plenty of new and uncured people to keep it spreading. Your $45 million goes down to $12.5 million and barely any profit if any at all. It would realistically bring the company a lot closer to break-even at best which is great but still no earnings level to even justify the current share price $12 to $100 ridiculous targets.
The SwingTrade Portfolio was up 36.2% in 2014, 83.5% in 2013, and 546.6% since inception.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110307454
Recent NNVC News
- In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides • ACCESS Newswire • 05/26/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2026 10:01:46 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2026 08:30:33 PM
- NanoViricides Announces Closing of ~$2 Million Registered Direct Offering • ACCESS Newswire • 05/19/2026 03:55:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/18/2026 12:45:22 PM
- Ebola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides • ACCESS Newswire • 05/18/2026 12:30:00 PM
- NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering • ACCESS Newswire • 05/15/2026 12:35:00 PM
- NanoViricides, Inc. Has Filed its Quarterly Report - NV-387 Advancing for Phase II • ACCESS Newswire • 05/15/2026 12:00:00 PM
- Recent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricides • ACCESS Newswire • 05/11/2026 12:30:00 PM
- NanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference • Newsfile • 05/06/2026 07:37:00 PM
- NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA • ACCESS Newswire • 05/04/2026 12:30:00 PM
- Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides • ACCESS Newswire • 04/21/2026 12:30:00 PM
- Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides • ACCESS Newswire • 04/07/2026 12:30:00 PM
- Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides • ACCESS Newswire • 04/01/2026 12:30:00 PM
- NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete • ACCESS Newswire • 03/11/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:30:47 PM
- MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/12/2026 01:30:00 PM
- Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/10/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/30/2025 09:30:18 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 12/16/2025 09:30:05 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/15/2025 09:26:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 09:30:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:32:10 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 07:54:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 04:29:54 PM
